Pharmacotherapeutic management of autism

Bibliography

• AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and Statistical Manua] of Mental Disorders(Edition 4). American Psychiatric Association, Washington, DC (1994).
   Google Scholar
• BRYSON SE: Epidemiology of autism: Overview and issues outstanding. In: Handbook of Autism and Pervasive Developmental Disorders (Edition 2). Cohen DJ, Volkmar FR (Eds) Wiley, New York (1997):41–46.
   Google Scholar
• POSEY DJ, MCDOUGLE CJ: The pharmacotherapy of target symptoms associated with autistic disorder and other pervasive developmental disorders. Harvard Rev. Psychiatry (2000) 8:45–63.
   PubMed Web of Science ®Google Scholar
• •A comprehensive review of medication treatment studies in autism from 1980-1999.
   Google Scholar
• CAMPBELL M, GELLER B, COHEN IL: Current status of drug research and treatment with autistic children. J Pediatr. Psycho]. (1977) 2:153–161.
   Google Scholar
• CAMPBELL M, ANDERSON LT, MEIER M et al.: A comparison of haloperidol and behavior therapy and their interaction in autistic children. J Am. Acad Child Adolesc. Psychiatry (1978) 17:640–655.
   Web of Science ®Google Scholar
• COHEN IL, CAMPBELL M, POSNER D, SMALL AM, TRIEBEL D, ANDERSON LT: Behavioral effects of haloperidol in young autistic children. J. Am. Acad. Child Adolesc. Psychiatry (1980) 19:665–677.
   Web of Science ®Google Scholar
• ANDERSON LT, CAMPBELL M, GREGA DM, PERRY R, SMALL AM, GREEN WH: Haloperidol in the treatment of infantile autism: Effects on learning and behavioral symptoms. Am. J. Psychiatry (1984) 141:1195–1202.
   PubMed Web of Science ®Google Scholar
• ANDERSON LT, CAMPBELL M, ADAMS P, SMALL AM, PERRY R, SHELL J: The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children./ Autism Dev. Disord. (1989) 19:227–239.
   PubMed Web of Science ®Google Scholar
• PERRY R, CAMPBELL M, ADAMS P et al.: long-term efficacy of haloperidol in autistic children: Continuous versus discontinuous drug administra-tion. J. Am. Acad. Child Adolesc. Psychiatry (1989) 28:87–92.
   PubMed Web of Science ®Google Scholar
• CAMPBELL M, ARMENTEROS JL, MALONE RP, ADAMS PB, EISENBERG ZW, OVERALL JE: Neur oleptic-r elated dyskinesias in autistic children: A prospective, longitudinal study. J. Am. Acad. Child Adolesc. Psychiatry (1997) 36:835–843.
   PubMed Web of Science ®Google Scholar
• NARUSE H, NAGAHATA M, NAKANE Y, SHIRAHASHI K, TAKESADA M, YAMAZAKI K: A multi-center double-blind trial of pimozide (Orap), haloperidol and placebo in children with behavioral disorders, using Exp. Opin. Pharmacother. (2001) 2(4) crossover design. Acta Paedopsychiatr. (1982) 48:173–184.
   Google Scholar
• ZUDDAS A, LEDDA MG, FRATTA A, MUGLIA P, CIANCHETTI C: Clinical effects of clozapine on autistic disorder. Am. J. Psychiatry (1996) 153:738.
   PubMed Web of Science ®Google Scholar
• VOLKMAR FR, NELSON DS: Seizure disorders in autism.J. Am. Acad. Child Adolesc. Psychiatry (1990) 29:127–129.
   PubMed Web of Science ®Google Scholar
• HARDAN A, JOHNSON K, JOHNSON C, HRECZNYJ B: Case study: Risperidone treatment of children and adoles-cents with developmental disorders. J. Am. Acad. Child Adolesc. Psychiatry (1996) 35:1551–1556.
   PubMed Web of Science ®Google Scholar
• FINDLING RL, MAXWELL K, WIZNITZER M: An open clinical trial of risperidone monotherapy in young children with autistic disorder. Psychopharmacol. (1997) 33:155–159.
   Web of Science ®Google Scholar
• MCDOUGLE CJ, HOLMES JP, BRONSON MR et al.: Risperi-done treatment of children and adolescents with pervasive developmental disorders: A prospective, open-label study. J. Am. Acad. Child Adolesc. Psychiatry (1997) 36:685–693.
   PubMed Web of Science ®Google Scholar
• NICOLSON R, AWAD G, SLOMAN L: An open trial of risperidone in young autistic children. J Am. Acad. Child Adolesc. Psychiatry (1998) 37:372–376.
   PubMed Web of Science ®Google Scholar
• MANDOKI M: Risperidone treatment of children and adolescents: Increased risk of ex trapyramidal side-effects? J. Child Adolesc. Psychopharmacol. (1995) 5:49–67.
   Web of Science ®Google Scholar
• MCDOUGLE CJ, HOLMES JP, CARLSON DC, PELTON GH, COHEN DJ, PRICE LH: A double-blind placebo-controlled study of riperidone in adults with autistic disorder and other pervasive developmental disorders. Arch. Gen. Psychiatry (1998) 55:633–641.
   PubMed Web of Science ®Google Scholar
• ••The only placebo-controlled study of an atypical antipsy-chotic in autism published to date.
   Google Scholar
• FISMAN S, STEELE M: Use of risperidone in pervasive developmental disorders: A case series. J Child Adolesc. Psychopharmacol. (1996) 6:177–190.
   PubMed Web of Science ®Google Scholar
• PERRY R, PATAKI C, MUNOZ-SILVA DM, ARMENTEROS J, SILVA R: Risperidone in children and adolescents with pervasive developmental disorder: Pilot trial and follow-up. J. Child Adolesc. Psychopharmacol. (1997) 7:167–179.
   PubMed Web of Science ®Google Scholar
• ZUDDAS A, DI MARTINO A, MUGLIA P, CIANCHETTI C: Long-term risperidone for pervasive developmental disorder: Efficacy, tolerability and discontinuation. J Child Adolesc. Psychopharmacol. (2000) 10:79–90.
   PubMed Web of Science ®Google Scholar
• MCDOUGLE CJ, SCAHILL L, MCCRACKEN JT et al.: Research Units on Pediatric Psychopharmacology (RUPP) Autism Network: Background and rationale for an initial controlled study of risperidone. Child. Adolesc. Psychiatric. Clin. N Am. (2000) 9:201–224.
   PubMed Web of Science ®Google Scholar
• POTENZA MN, HOLMES JP, KANES SJ, MCDOUGLE CJ: Olanzapine treatment of children, adolescents and adults with pervasive developmental disorders: An open-label pilot study. J. Clin. Psychopharmacol. (1999) 19:37–44.
   PubMed Web of Science ®Google Scholar
• WIRSHING DA, WIRSHING WC, KYSAR L et al.: Novel antipsychotics: Comparison of weight gain liabilities. Clin. Psychiatry (1999) 60:358–363.
   PubMed Web of Science ®Google Scholar
• MARTIN A, KOENIG K, SCAHILL L, BREGMAN J: Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc. Psychopharmacol (1999) 9:99–107.
   PubMed Web of Science ®Google Scholar
• FINDLING RL, MCNAMARA NK, GRACIOUS BL: Paediatric uses of atypical antipsychotics. Exp. Opin. Pharmaco-ther. (2000) 1:935–945.
   PubMedGoogle Scholar
• SALLEE FR, KURLAN R, GOETZ CG et al.: Ziprasidone treatment of children and adolescents with Tourette's syndrome: A pilot study. J. Am. Acad. Child Adolesc. Psychiatry (2000) 39:292–299.
   PubMed Web of Science ®Google Scholar
• SCHAIN RJ, FREEDMAN DX: Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children. J. Pediatr. (1961) 58:315–320.
   PubMed Web of Science ®Google Scholar
• MCDOUGLE CJ, KRESCH LE, POSEY DJ: Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibi-tors. J. Autism Dev. Disord. (2000) 30:427–435.
   PubMed Web of Science ®Google Scholar
• GORDON CT, STATE RC, NELSON JE, HAMBURGER SD, RAPAPORT JL: A double-blind comparison of clomipramine, desipramine and placebo in the treatment of autistic disorder. Arch. Gen. Psychiatry (1993) 50:441–447.
   PubMed Web of Science ®Google Scholar
• BRODKIN ES, MCDOUGLE CJ, NAYLOR ST, COHEN DJ, PRICE LH: Clomipramine in adults with pervasive developmental disorders: A prospective open-label investigation. J Child Adolesc. Psychopharmacol. (1997) 7:109–121.
   PubMed Web of Science ®Google Scholar
• SLOMAN L, NICHOLSON R: Medication in pervasive developmental disorder. Child Adolesc. Psychophar-macol. News (1999) 4:4–9.
   Google Scholar
• SANCHEZ LE, CAMPBELL M, SMALL AM, CUEVA JE, ARMENTEROS JL, ADAMS PB: A pilot study of clomipramine in young autistic children. J Am. Acad. Child Adolesc. Psychiatry (1996) 35:537–544.
   PubMed Web of Science ®Google Scholar
• MCDOUGLE CJ, NAYLOR ST, COHEN DJ, VOLKMAR FR, HENINGER GR, PRICE LH: A double-blind, placebo-controlled study of fluvox amine in adults with autistic disorder. Arch. Gen. Psychiatry (1996) 53:1001–1008.
   PubMed Web of Science ®Google Scholar
• ••The only placebo-controlled study of an SSRI in autismpublished to date.
   Google Scholar
• RIDDLE MA, REEVE EA, YARYURA-TOBIAS J etal.: Fluvox - amine for children and adolescents with obsessive-compulsive disorder: A randomized, controlled, multicenter trial. J. Am. Acad. Child Adolesc. Psychiatry (2001) 40:222–229.
   PubMed Web of Science ®Google Scholar
• COOK EH, ROWLETT R, JASELSKIS C, LEVENTHAL BL: Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Am. Acad. Child Adolesc. Psychiatry (1992) 31:739–745.
   PubMed Web of Science ®Google Scholar
• BRANFORD D, BHAUMIK S, NAIK B: Selective serotonin re-uptake inhibitors for the treatment of perseverative and maladaptive behaviours of people with intellec-tual disability. J. Intellect. Disabil Res. (1998) 42:301–306.
   PubMed Web of Science ®Google Scholar
• DELONG GR, TEAGUE LA, KAMRAN MM: Effects of fluoxetine treatment in young children with idiopathic autism. Dev. Med. Child Neurof (1998) 40:551–562.
   PubMed Web of Science ®Google Scholar
• MCDOUGLE CJ, BRODKIN ES, NAYLOR ST, CARLSON DC,COHEN DJ, PRICE LH: Sertraline in adults with pervasive developmental disorders: A prospective open-label investigation. J. Clin. Psychopharmacol. (1998) 18:62–66.
   PubMed Web of Science ®Google Scholar
• DAVANZO PA, BELIN TR, WIDAWSKI MH, KING BH. Paroxetine treatment of aggression and self-injury in persons with mental retardation. Am. J Ment. Retard. (1998) 102:427–437.
   PubMedGoogle Scholar
• JASELSKIS CA, COOK EH JR, FLETCHER KE, LEVENTHALBL: Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin. Psychophar-macol. (1992) 12:322–327.
   PubMed Web of Science ®Google Scholar
• FANKHAUSER MP, KARUMANCHI VC, GERMAN ML, YATES A, KARUMANCHI SD: A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. J Clin. Psychiatry (1992) 53:77–82.
   PubMed Web of Science ®Google Scholar
• BIRMAHER B, QUINTANA H, GREENHILL LL: Methylphenidate treatment of hyperactive autistic children. J. Am. Acad. Child Adolesc. Psychiatry (1988) 27:248–251.
   PubMed Web of Science ®Google Scholar
• QUINTANA H, BIRMAHER B, STEDGE D et al: Use ofmethylphenidate in the treatment of children with autistic disorder. J. Autism Dev. Disord. (1995) 25:283–294.
   PubMed Web of Science ®Google Scholar
• HANDEN BL, JOHNSON CR, LUBETSKY M: Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J. Autism Dev. Disord. (2000) 30:245–255.
   PubMed Web of Science ®Google Scholar
• CAMPBELL M, ANDERSON LT, SMALL AM, ADAMS P, GONZALEZ NM, ERNST M: Naltrex one in autistic children: Behavioral symptoms and attentional learning. J. Am. Acad. Child Adolesc. Psychiatry (1993) 3 2:1283–1291.
   Google Scholar
• WILLEMSEN-SWINKELS SHN, BUITELAAR JK, NIJHOF GJ,VAN ENGELAND H: Failure of naltrexone hydrochlo-ride to reduce self-injurious and autistic behavior in mentally retarded adults. Arch. Gen. Psychiatry (1995) 52:766–773.
   PubMedGoogle Scholar
• WILLEMSEN-SWINKELS SHN, BUITELAAR JK, WEIJNEN FG, VAN ENGELAND H: Placebo-controlled acute dosage naltrex one study in young autistic children. Psychiatry Res. (1995) 58:203–215.
   PubMedGoogle Scholar
• KOLMAN BK, FELDMAN HM, HANDEN BL, JANOSKY JE: Naltrex one in young autistic children: A double-blind placebo-controlled crossover study. J. Am. Acad. Child Adolesc. Psychiatry (1995) 34:223–231.
   PubMedGoogle Scholar
• WILLEMSEN-SWINKELS SHN, BUITELAAR JK, VAN ENGELAND H: The effects of chronic naltrex one treatment in young autistic children: A double-blind placebo-controlled crossover study. Biol. Psychiatry (1996) 39:1023–1031.
   PubMedGoogle Scholar
• KOLMEN BK, FELDMAN HM, HANDEN BL, JANOSKY JE: Naltrexone in young autistic children: replication study and learning measures. J. Am. Acad. Child Adolesc. Psychiatry (1997) 36:1570–1578.
   PubMed Web of Science ®Google Scholar
• KING BH, COOK EH, SIKICH L et al.: A controlled trial of amantadine in the treatment of autistic children. The Scientific Proceedings of the 46th Annual Meeting of the American Academy of Child & Adolescent Psychiatry. Chicago, IL, USA (2000129.
   Google Scholar
• UVEBRANT P, BAUZIENE R: IntracTabie epilepsy in children. The efficacy of lamotrigine treatment, including n -s eizur e-r elated benefits. Neuropediatrks (1994) 25:284–289.
   Google Scholar
• HOLLANDER E, DOLGOFF-KASPAR R, CARTWRIGHT C,RAWITT R, NOVOTNY S: Divalproex sodium in autism spectrum disorders: a pilot trial. (NCDEU Abstract). J Child Adolesc. Psychopharmacol (2000) 10 (4):251–252.
   Google Scholar
• POSEY DJ, GUENIN K, KOHBURN A, SWIEZY N, MCDOUGLE C: An open-label trial of mirtazapine in autism and related disorders. The Scientific Proceedings of the 47th Annual Meeting of the American Academy of Child & Adolescent Psychiatry. New York, NY (2000):127.
   Google Scholar
• HOLLANDER E, KAPLAN A, CARTVVRIGHT C, REICHMAN D: Venlafaxine in children, adolescents and young adults with autism spectrum disorders: an open retrospective clinical report. J. Child Neurol (2000) 15:132–135.
   PubMed Web of Science ®Google Scholar
• KING BH, DAVANZO P: Buspir one treatment of aggres-sion and self-injury in autistic and nonautistic persons with severe mental retardation. Dev. Brain Dysfunct. (1996) 9:22–31.
   Google Scholar
• BUITELAAR JK, VAN DER GAAG RJ, VAN DER HOEVEN J: Buspirone in the management of anxiety and irrita-bility in children with pervasive developmental disorders: Results of an open-label study. J Clin. Psychiatry (1998) 59:56–59.
   PubMed Web of Science ®Google Scholar
• RATEY JJ, MIKKELSEN E, SORGI P et al.: Autism: The treatment of aggressive behaviors. J. Clin. Psychophar-macol. (1987) 7:35–41.
   PubMed Web of Science ®Google Scholar
• CHEZ MG, NOWINSKI CV, BUCHANAN CP, JONES C: Donepezil (Aricept) use in children with autistic spectrum disorders. Am. Neurol (2000) 48:541.
   Google Scholar
• HORVATH K, STEFANATOS G, SOKOLSKI KN, WACHTELR, NABORS L, TILDON JT: Improved social and language skills after secretin administration in patients with autistic spectrum disorders. J. Assoc. Acad. Minor. Phys. (1998) 9:9–15.
   PubMedGoogle Scholar
• SANDLER AD, SUTTON KA, DEWEESE J, GIRARDI MA, SHEPPARD V, BODFISH JW: lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder. N Engl. J. Med. (1999) 341:1801–1806.
   PubMed Web of Science ®Google Scholar
• •The largest of the placebo-controlled studies of secretin in autism that found no difference from placebo.
   Google Scholar
• CHEZ MG, BUCHANAN CP, BAGAN BT etal.: Seer etin and autism: a two-part clinical investigation. J Autism Dev. Disord. (2000) 30:87–94.
   PubMedGoogle Scholar
• •Another placebo-controlled study of secretin in autism that found no difference from placebo.
   Google Scholar
• DELGIUDICE-ASCH G, SIMON L, SCHMEIDLER J, CUNNINGHAM-RUNDLES C, HOLLANDER E: Brief r ep or t: a pilot open clinical trial of intravenous immuno-globulin in childhood autism. J. Autism Dev. Disord. (1999) 29:157–160.
   PubMed Web of Science ®Google Scholar
• BOLTE ER: Autism and Clostridium tetani. Medical Hypotheses (1998) 51:133–144.
   PubMed Web of Science ®Google Scholar
• SANDLER RH, FINEGOLD SM, BOLTE ER et al.: Short-termbenefit from oral vancomycin treatment of regressive-onset autism. J. Child. Neurol. (2000) 15:429–435.
   PubMed Web of Science ®Google Scholar
• http://www.medscape.com OWLEY T, STEELE E, CORSELLO C et al.: A double-blind, placebo-controlled trial of secretin for the treatment of autistic disorder. Medscape Gen. Med. (1999) 1(10).
   Google Scholar
• •The first of the placebo-controlled studies of secretin in autism that found no difference from placebo.
   Google Scholar